Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

• Status: Completed
• Trial end date: 2004-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS methylphenidate and placebo. Each week, parent report measures, clinical interviews, and safety assessments are conducted.

Hypothesis: Efficacy and adverse events will be dose dependent. Dopamine Transporter Genotype will predict response

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Illinois at Chicago
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• 6-17 DSM IV criteria for ADHD Parents willing to complete measures

Exclusion Criteria:

• Mental retardation psychoses seizure disorder